Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| APL-H5263 | Human | Human APRIL / TNFSF13 Protein, Fc Tag |  |
|
|
| APL-H82Q8 | Human | Biotinylated Human APRIL / TNFSF13 Protein, Avitag™,His Tag, active trimer (MALS verified) |
|
|
|
| APL-C52D2 | Cynomolgus | Cynomolgus APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified) |
|
|
|
| APL-H52D1 | Human | Human APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified) |
|
|
|
| APL-H82F5 | Human | Biotinylated Human APRIL / TNFSF13 Protein, Fc,Avitag™ |  |
|
|
Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with an affinity constant of 1.88 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Telitacicept | RCT-18; RC-18; RCT18; RC18 | Approved | RemeGen Co Ltd | 泰爱 | Mainland China | Lupus Erythematosus, Systemic | RemeGen Co Ltd | 2021-03-09 | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Erythematosus, Systemic; Neuromyelitis Optica | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| AUR-200 | AUR-200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| RO-7297089 | RO-7297089; AFM-26; RG-6296 | Genentech Inc | Details | ||
| anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital） | Phase 1 Clinical | Massachusetts General Hospital | Multiple Myeloma | Details | |
| ALPN-303 | ALPN-303 | Phase 1 Clinical | Alpine Immune Sciences Inc | Sjogren's Syndrome; Lupus Erythematosus, Systemic | Details |
| APRIL CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Sibeprenlimab | VIS-649 | Phase 3 Clinical | Visterra Inc | Glomerulonephritis, IGA; Glomerulonephritis | Details |
| Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
| BION-1301 | BION-1301 | Phase 2 Clinical | Aduro Biotech Inc | Glomerulonephritis, IGA; Multiple Myeloma | Details |
| Atacicept | TACI-Ig | Phase 3 Clinical | Zymogenetics Inc | Glomerulonephritis, IGA; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
This web search service is supported by Google Inc.
A-Z
